司库奇尤单抗治疗银屑病专家共识  

Expert consensus on clinical use of secukinumab in the treatment of psoriasis

作　　者：《司库奇尤单抗治疗银屑病专家共识》编写组 张建中[2] 蔡林[2] Working Group on“Expert consensus on clinical use of secukinumab in the treatment of psoriasis”;Zhang Jianzhong

机构地区：[1]不详 [2]北京大学人民医院

出　　处：《中华皮肤科杂志》2024年第12期1079-1090,共12页Chinese Journal of Dermatology

摘　　要：银屑病是一种免疫介导的、慢性、炎症性、系统性疾病,可发生于任何年龄,严重影响生活质量。白细胞介素17A是银屑病发病的重要炎症因子,司库奇尤单抗是全球首个白细胞介素17A的单克隆抗体,在中国获批治疗中重度斑块状银屑病的6岁及以上患者、活动性银屑病关节炎成人患者和强直性脊柱炎成人患者。上市以来,我国积累了大量真实世界疗效和安全性数据。本文对司库奇尤单抗的长期疗效与安全性、长期使用策略、特殊患者的使用等进行系统综述并形成了专家共识,目的是促进司库奇尤单抗的规范化应用。Psoriasis is an immune-mediated,chronic,inflammatory and systemic disease that can occur at any age and has a profound impact on patients′quality of life.Interleukin-17A is a key pro-inflammatory cytokine involved in the pathogenesis of psoriasis.Secukinumab is a fully human anti-interleukin-17A monoclonal antibody.It is approved in China for the treatment of moderate‐to‐severe plaque psoriasis in patients aged 6 years or older,active psoriatic arthritis in adults and ankylosing spondylitis in adults.Since its launch,a large amount of real‐world data on the efficacy and safety has been accumulated in China.To standardize the use of secukinumab in the long‐term management of psoriasis,a systematic review of the literature on the long-term efficacy and safety of secukinumab as well as its treatment strategies and use in special populations was conducted,and an expert consensus was proposed.

关 键 词：银屑病 司库奇尤单抗 治疗 疾病管理 长程管理 专家共识 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]